12578 Assessment Of Sarcopenic Obesity in Patients with Acromegaly

Abstract Disclosure: C.P. Rocha: None. N.N. Hupalowski: None. S.Z. Fidalski: None. C.L. Boguszewski: Consulting Fee; Self; Recordati. Research Investigator; Self; Crinetics. Speaker; Self; Ipsen, Novo Nordisk. V.Z. Borba: None. Introduction: Patients with acromegaly in activity exhibit modifications in body composition with increased skeletal muscle mass and decreased body fat. The effects of growth hormone on muscle strength and performance are uncertain, suggesting possible changes in physical performance due to compromised strength and functioning of skeletal muscle not correlated with total lean body mass. Sarcopenia is a progressive disorder of skeletal muscle, associated with risk of falls, fractures, loss of autonomy, and increased mortality, sarcopenic obesity is defined as the coexistence of both comorbidities. Objective: To assess sarcopenic obesity in patients with acromegaly compared to controls. Patients and Methods: observational, case-control study, matched 1:1 by age and sex with a control group. The study was approved by the ethics committee and individuals included after formal consent. The study group patients under clinical follow-up at a reference service in southern Brazil. All individuals underwent clinical evaluation through questionnaires; muscle strength [sit-to-stand test (STST5x) and hand grip strength (HGS)]; muscle mass quantification by dual-energy X-ray absorptiometry (DXA) and physical performance [Gait Speed, the Short Physical Performance Battery (SPPB), and the Timed-Up and Go test (TUG)]. Sarcopenic obesity was calculated following the ESPEN and EASO consensus. Results: The study population included matched 48 patients with acromegaly and 48 controls matched 1:1 by age and sex. The population was predominantly female (54.1%), mean age of 56.31 ± 11.60 years, with 79.1% below 65 years of age, and 64.58% (31) were in inactive acromegaly. The mean weight was 87.88 ± 18.02 kg, and the mean BMI was 31.25 ± 4.95. Mean muscle lean mass was higher in the patient group, and the diagnosis of sarcopenic obesity was similar between groups. However, all performance tests were worst in patients than controls with altered tests: TSL5X in 24 (50%) vs 2 (4,3%) controls; gait speed test in 14 (29.2%) vs. 3 (6,4%) controls and in the SPPB in 15 (31.37%) vs 0 (0%) controls, p<0.005 for all. The investigation of sarcopenia in patients with active or inactive disease did not show significant differences. Conclusion: We identified in a population of patients with acromegaly a low performance despite of a preserved lean mass and similar diagnosis of sarcopenic obesity. This study highlights the impairment of physical performance and functionality, not reflecting the adequate muscular amount in patients with acromegaly. Presentation: 6/2/2024